#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Glycogen storage disease type II

Recruiting

InvestigationalNo placebo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Glycogen storage disease type II

Recruiting

Investigational

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational

Germany

Participants:18–64 years

Contact Research Centre

Study on the Effectiveness and Safety of Nizubaglustat in Patients with Niemann-Pick Type C, GM1, or GM2 Gangliosidosis

Recruiting

Investigational

Study on the Effectiveness and Safety of Nizubaglustat in Patients with Niemann-Pick Type C, GM1, or GM2 Gangliosidosis

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:NIZUBAGLUSTAT

Contact Research Centre

Mucopolysaccharidosis II

Recruiting

InvestigationalNo placebo

Long-term Safety and Efficacy Study of JR-141 (Pabinafusp Alfa) for Male Patients with Hunter Syndrome (Mucopolysaccharidosis II)

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pabinafusp Alfa

Contact Research Centre

Study on N-Acetyl-L-Leucine for Patients with Niemann-Pick Disease Type C

Recruiting

Investigational

Study on N-Acetyl-L-Leucine for Patients with Niemann-Pick Disease Type C

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:L-Acetylleucine

Contact Research Centre

Glycogen storage disease type II

Recruiting

InvestigationalNo placebo

Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:Cipaglucosidase Alfa

Contact Research Centre

Mucopolysaccharidosis II

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor

Contact Research Centre

Gaucher's disease type III

Not yet recruiting

Registered drugNo placebo

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Imiglucerase

Contact Research Centre

Gaucher's disease type I

Not yet recruiting

Registered drugNo placebo

Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Eculizumab

Contact Research Centre

Respiratory syncytial virus infection+3

Not recruiting

Registered drugNo placebo

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Contact Research Centre

Fabry's disease

Not recruiting

Registered drugNo placebo

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:AGALSIDASE BETA

Contact Research Centre

Herpes zoster

Not recruiting

Registered drugNo placebo

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Recombinant Varicella Zoster Virus Glycoprotein E

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.